A Therapeutic Strategy for Chemotherapy-Resistant Gastric Cancer via Destabilization of Both β-Catenin and RAS

Treatment of advanced gastric cancer patients with current standard chemotherapeutic agents frequently results in resistance, leading to poor overall survival. However, there has been no success in developing strategies to overcome it. We showed the expression levels of both β-catenin and RAS were significantly increased and correlated in tissues of 756 gastric cancer (GC) patients and tissues of primary- and acquired-resistance patient-derived xenograft tumors treated with 5-fluorouracil and oxaliplatin modulated with leucovorin (FOLFOX). On the basis of our previous studies, where small molecules to suppress colorectal cancer (CRC) via degrading both β-catenin and RAS were developed, we tested the effectiveness of KYA1797K, a representative compound functioning by binding axin, in the growth of GC cells. The efficacy test of the drugs using gastric tumor organoids of Apc1638N mice showed that the CD44 and ALDH1A3 cancer stem cell markers were induced by FOLFOX, but not by KYA1797K. KYA1797K also efficiently suppressed tumors generated by re-engrafting the FOLFOX-resistant patient-derived xenograft (PDX) tumors, which also showed resistance to paclitaxel. Overall, the small-molecule approach degrading both β-catenin and RAS has potential as a therapeutic strategy for treating GC patients resistant to current standard chemotherapies.

[1]  S. Carr,et al.  Author Correction: Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition , 2018, Nature Medicine.

[2]  Andrea Sottoriva,et al.  Patient-derived organoids model treatment response of metastatic gastrointestinal cancers , 2018, Science.

[3]  Ki-Sook Park,et al.  KY1022, a small molecule destabilizing Ras via targeting the Wnt/β-catenin pathway, inhibits development of metastatic colorectal cancer , 2016, Oncotarget.

[4]  Panagiotis Kotsantis,et al.  Increased global transcription activity as a mechanism of replication stress in cancer , 2016, Nature Communications.

[5]  Mi-Yeon Kim,et al.  Small-molecule binding of the axin RGS domain promotes β-catenin and Ras degradation. , 2016, Nature chemical biology.

[6]  W. Zhou,et al.  Aldehyde dehydrogenase 3A1 is robustly upregulated in gastric cancer stem-like cells and associated with tumorigenesis. , 2016, International journal of oncology.

[7]  Yoon Young Choi,et al.  Establishment and characterisation of patient-derived xenografts as paraclinical models for gastric cancer , 2016, Scientific Reports.

[8]  Anushya Muruganujan,et al.  PANTHER version 10: expanded protein families and functions, and analysis tools , 2015, Nucleic Acids Res..

[9]  Yoon Young Choi,et al.  The benefit of microsatellite instability is attenuated by chemotherapy in stage II and stage III gastric cancer: Results from a large cohort with subgroup analyses , 2015, International journal of cancer.

[10]  Fabian J Theis,et al.  A subset of metastatic pancreatic ductal adenocarcinomas depends quantitatively on oncogenic Kras/Mek/Erk-induced hyperactive mTOR signalling , 2015, Gut.

[11]  D. Fan,et al.  Loss of vinculin and membrane-bound β-catenin promotes metastasis and predicts poor prognosis in colorectal cancer , 2014, Molecular Cancer.

[12]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of gastric adenocarcinoma , 2014, Nature.

[13]  Joon-Oh Park,et al.  Clinical Practice Guidelines for Gastric Cancer in Korea: An Evidence-Based Approach , 2014, Journal of gastric cancer.

[14]  Kang-Yell Choi,et al.  Role of oncogenic K-Ras in cancer stem cell activation by aberrant Wnt/β-catenin signaling. , 2014, Journal of the National Cancer Institute.

[15]  Roopma Wadhwa,et al.  Gastric cancer—molecular and clinical dimensions , 2013, Nature Reviews Clinical Oncology.

[16]  Anushya Muruganujan,et al.  Large-scale gene function analysis with the PANTHER classification system , 2013, Nature Protocols.

[17]  Cole Trapnell,et al.  TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions , 2013, Genome Biology.

[18]  Jeremy Wazny,et al.  Xenome—a tool for classifying reads from xenograft samples , 2012, Bioinform..

[19]  Hoguen Kim,et al.  Ras Stabilization Through Aberrant Activation of Wnt/β-Catenin Signaling Promotes Intestinal Tumorigenesis , 2012, Science Signaling.

[20]  J. Hancock,et al.  Ras trafficking, localization and compartmentalized signalling. , 2012, Seminars in cell & developmental biology.

[21]  David R. Kelley,et al.  Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks , 2012, Nature Protocols.

[22]  Sorin V. Sabau,et al.  A novel method, digital genome scanning detects KRAS gene amplification in gastric cancers: involvement of overexpressed wild-type KRAS in downstream signaling and cancer cell growth , 2009, BMC Cancer.

[23]  O. Sokolova,et al.  Helicobacter pylori Suppresses Glycogen Synthase Kinase 3β to Promote β-Catenin Activity* , 2008, Journal of Biological Chemistry.

[24]  B. Williams,et al.  Mapping and quantifying mammalian transcriptomes by RNA-Seq , 2008, Nature Methods.

[25]  Y. Jeon,et al.  EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number , 2008, Histopathology.

[26]  Julie A. Wilkins,et al.  Loss of Apc allows phenotypic manifestation of the transforming properties of an endogenous K-ras oncogene in vivo , 2006, Proceedings of the National Academy of Sciences.

[27]  V. Panuccio,et al.  First line chemotherapy with FOLFOX 4 in elderly patients (>65 years) with advanced or metastatic gastric cancer (A/MGC): A pilot study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Washington,et al.  Activation of β-catenin by carcinogenic Helicobacter pylori , 2005 .

[29]  S. Schwartz,et al.  BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency , 2003, Oncogene.

[30]  N. Lunet,et al.  Helicobacter pylori infection and gastric cancer: Facing the enigmas , 2003, International journal of cancer.

[31]  T. Bauknecht,et al.  A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. , 2003, Journal of the National Cancer Institute.

[32]  Y. Yuasa.  Control of gut differentiation and intestinal-type gastric carcinogenesis , 2003, Nature Reviews Cancer.

[33]  E. Van Cutsem,et al.  Current treatments and future perspectives in colorectal and gastric cancer. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  Min-Cheol Lee,et al.  Inverse relationship between APC gene mutation in gastric adenomas and development of adenocarcinoma. , 2002, The American journal of pathology.

[35]  H. Clevers,et al.  APC, Signal transduction and genetic instability in colorectal cancer , 2001, Nature Reviews Cancer.

[36]  N. Sasaki,et al.  Helicobacter pylori infection and the development of gastric cancer. , 2001, The New England journal of medicine.

[37]  H Clevers,et al.  Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway. , 1999, The American journal of pathology.

[38]  Y. Shimada,et al.  An early phase II study of a 3-hour infusion of paclitaxel for advanced gastric cancer. , 1998, American journal of clinical oncology.

[39]  A. Burgess,et al.  Synergy between Apc min and an activated ras mutation is sufficient to induce colon carcinomas , 1996, Molecular and cellular biology.

[40]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[41]  Huaiyu Mi,et al.  PANTHER pathway: an ontology-based pathway database coupled with data analysis tools. , 2009, Methods in molecular biology.

[42]  N. Barker,et al.  Detection of beta-catenin localization by immunohistochemistry. , 2008, Methods in molecular biology.

[43]  M. Washington,et al.  Activation of beta-catenin by carcinogenic Helicobacter pylori. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[44]  M. Gottesman,et al.  Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.